Interestingly, the downregulation of the cGAS/STING pathway itself was shown to be a predictive biomarker for certain cancer subtypes, opening up the potential to identify patient groups that could benefit from cGAS/STING re-enhancing immunotherapy agents such as ENPP1 or TREX1 inhibitors. The gene discussed is CGAS; the disease is cancer.